Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 11
2021 13
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.
Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M, Smura T, Levanov L, Szirovicza L, Tobi A, Kallio-Kokko H, Österlund P, Joensuu M, Meunier FA, Butcher SJ, Winkler MS, Mollenhauer B, Helenius A, Gokce O, Teesalu T, Hepojoki J, Vapalahti O, Stadelmann C, Balistreri G, Simons M. Cantuti-Castelvetri L, et al. Science. 2020 Nov 13;370(6518):856-860. doi: 10.1126/science.abd2985. Epub 2020 Oct 20. Science. 2020. PMID: 33082293 Free PMC article.
The causative agent of coronavirus disease 2019 (COVID-19) is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ...Pathological analysis of olfactory epithelium obtained from human COVID-19 autopsies revealed …
The causative agent of coronavirus disease 2019 (COVID-19) is the severe acute respiratory syndrome coronavirus 2 (S
A serological assay to detect SARS-CoV-2 seroconversion in humans.
Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V, Krammer F. Amanat F, et al. Nat Med. 2020 Jul;26(7):1033-1036. doi: 10.1038/s41591-020-0913-5. Epub 2020 May 12. Nat Med. 2020. PMID: 32398876 Free PMC article.
Here, we describe a serological enzyme-linked immunosorbent assay for the screening and identification of human SARS-CoV-2 seroconverters. This assay does not require the handling of infectious virus, can be adjusted to detect different antibody types in seru …
Here, we describe a serological enzyme-linked immunosorbent assay for the screening and identification of human SARS-CoV-2
Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation.
Jääskeläinen AJ, Kuivanen S, Kekäläinen E, Ahava MJ, Loginov R, Kallio-Kokko H, Vapalahti O, Jarva H, Kurkela S, Lappalainen M. Jääskeläinen AJ, et al. J Clin Virol. 2020 Aug;129:104512. doi: 10.1016/j.jcv.2020.104512. Epub 2020 Jun 15. J Clin Virol. 2020. PMID: 32563180 Free PMC article.
We compared the performance of six commercial immunoassays for the detection of SARS-COV-2 IgG, IgA and IgM antibodies, including four automated assays [Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison SARS-COV-2 S …
We compared the performance of six commercial immunoassays for the detection of SARS-COV-2 IgG, IgA and IgM antibodies, …
Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples.
Jääskeläinen AJ, Kekäläinen E, Kallio-Kokko H, Mannonen L, Kortela E, Vapalahti O, Kurkela S, Lappalainen M. Jääskeläinen AJ, et al. Euro Surveill. 2020 May;25(18):2000603. doi: 10.2807/1560-7917.ES.2020.25.18.2000603. Euro Surveill. 2020. PMID: 32400364 Free PMC article.
Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lubeck, Germa …
Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be val …
Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020.
Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, Melidou A, Neher RA, O'Toole Á, Pereyaslov D; WHO European Region sequencing laboratories and GISAID EpiCoV group; WHO European Region sequencing laboratories and GISAID EpiCoV group*. Alm E, et al. Euro Surveill. 2020 Aug;25(32):2001410. doi: 10.2807/1560-7917.ES.2020.25.32.2001410. Euro Surveill. 2020. PMID: 32794443 Free PMC article.
We show the distribution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic clades over time and between countries and outline potential genomic surveillance objectives. ...We highlight the importance of real-time sequencing and da …
We show the distribution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic clades over tim …
A serological assay to detect SARS-CoV-2 seroconversion in humans.
Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Asthagiri Arunkumar G, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L, Fierer D, Amarilis Lugo L, Milunka Kojic E, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran T, Garcia-Sastre A, Caplivski D, Cheng A, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V, Krammer F. Amanat F, et al. medRxiv. 2020 Apr 16:2020.03.17.20037713. doi: 10.1101/2020.03.17.20037713. Preprint. medRxiv. 2020. PMID: 32511441 Free PMC article. Updated.
SARS-Cov-2 (severe acute respiratory disease coronavirus 2), which causes Coronavirus Disease 2019 (COVID19) was first detected in China in late 2019 and has since then caused a global pandemic. While molecular assays to directly detect the viral genet
SARS-Cov-2 (severe acute respiratory disease coronavirus 2), which causes Coronavirus Disease 2019 (COVID19) was
Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19.
Rodriguez L, Pekkarinen PT, Lakshmikanth T, Tan Z, Consiglio CR, Pou C, Chen Y, Mugabo CH, Nguyen NA, Nowlan K, Strandin T, Levanov L, Mikes J, Wang J, Kantele A, Hepojoki J, Vapalahti O, Heinonen S, Kekäläinen E, Brodin P. Rodriguez L, et al. Cell Rep Med. 2020 Aug 25;1(5):100078. doi: 10.1016/j.xcrm.2020.100078. Epub 2020 Aug 5. Cell Rep Med. 2020. PMID: 32838342 Free PMC article.
Severe disease of SARS-CoV-2 is characterized by vigorous inflammatory responses in the lung, often with a sudden onset after 5-7 days of stable disease. ...We also map an immune trajectory during recovery that is shared among patients with severe COVID
Severe disease of SARS-CoV-2 is characterized by vigorous inflammatory responses in the lung, often with a sudden onset …
Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020.
Haveri A, Smura T, Kuivanen S, Österlund P, Hepojoki J, Ikonen N, Pitkäpaasi M, Blomqvist S, Rönkkö E, Kantele A, Strandin T, Kallio-Kokko H, Mannonen L, Lappalainen M, Broas M, Jiang M, Siira L, Salminen M, Puumalainen T, Sane J, Melin M, Vapalahti O, Savolainen-Kopra C. Haveri A, et al. Euro Surveill. 2020 Mar;25(11):2000266. doi: 10.2807/1560-7917.ES.2020.25.11.2000266. Euro Surveill. 2020. PMID: 32209163 Free PMC article.
The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3-23 days since the first symptoms. The SARS-CoV-2/Finland/1 …
The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected …
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R, Maljanen S, Reinholm A, Tauriainen S, Pakkanen SH, Levonen I, Nousiainen A, Miller T, Välimaa H, Ivaska L, Pasternack A, Naves R, Ritvos O, Österlund P, Kuivanen S, Smura T, Hepojoki J, Vapalahti O, Lempainen J, Kakkola L, Kantele A, Julkunen I. Jalkanen P, et al. Nat Commun. 2021 Jun 28;12(1):3991. doi: 10.1038/s41467-021-24285-4. Nat Commun. 2021. PMID: 34183681 Free PMC article.
As SARS-CoV-2 has been circulating for over a year, dozens of vaccine candidates are under development or in clinical use. ...The vaccinees' neutralization titres exceeded those of recovered non-hospitalized COVID-19 patients. Our work provides …
As SARS-CoV-2 has been circulating for over a year, dozens of vaccine candidates are under development or in clinical u …
Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19.
Haljasmägi L, Salumets A, Rumm AP, Jürgenson M, Krassohhina E, Remm A, Sein H, Kareinen L, Vapalahti O, Sironen T, Peterson H, Milani L, Tamm A, Hayday A, Kisand K, Peterson P. Haljasmägi L, et al. Sci Rep. 2020 Nov 25;10(1):20533. doi: 10.1038/s41598-020-77525-w. Sci Rep. 2020. PMID: 33239683 Free PMC article.
SARS-CoV-2 infection has a risk to develop into life-threatening COVID-19 disease. ...To this end, we longitudinally profiled blood inflammation markers, antibodies, and 101 plasma proteins of hospitalized COVID-19 patients who did
SARS-CoV-2 infection has a risk to develop into life-threatening COVID-19 disease. ...To this end, we lon
22 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page